在中国，Entresto已被批准治疗射血分数降低心力衰竭(HFrEF)。 2021年02月17日讯 /生物谷BIOON/ --诺华（Novartis）近日宣布，美国食品 ...

日前，根据诺华在欧洲心脏病学会年会上发表的最新报告，Entresto在改善射血分数不变的心力衰竭（HFpEF）患者的症状严重程度和心脏功能方面取得了 ...

本周二，美国食品和药物管理局（FDA）批准诺华制药（Novartis）的心衰药物Entresto（中文商品名：诺欣妥，sacubitril/valsartan ...

事件概述 2023 年7 月7 日，诺华公司官网发布新闻稿，其中提到美国特拉华州地区法院裁定Entresto（sacubitril/valsartan）“组合 ...

In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the risk of cardiovascular death or heart failure hospitalisation by 20 per cent ...

得益于Entresto、Kesimpta、Pluvicto和Kisqali的优异表现，今年二季度，诺华实现了强劲的销售增长和利润率扩张，因此提高了全年业绩指引：销售额增长 ...

The above diagram shows the results from the PARADIGM-HF study, comparing Entresto with angiotensin converting enzyme (or ACE) inhibitor therapy, enalapril, in head-to-head trial programs ...

ZURICH (Reuters) - Novartis's heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction.

ZURICH (Reuters) - Novartis's heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction. Novartis, ...

Novartis has unveiled a major clinical trial programme for Entresto as it tries to kick-start sales of the heart failure drug. Described as the “largest global ...

A multinational, randomized, double-blind trial comparing Entresto versus enalapril in 8,442 adult patients with symptomatic chronic heart failure (NYHA class II–IV) and systolic dysfunction ...